Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Theracell Advanced Biotechnology develops advanced cell and gene therapies targeting orthopedic, dermatological, nephrological conditions as well as oncology and chronic inflammatory/metabolic diseases. Its lead programs use mesenchymal stromal cells for bone/joint/tissue regeneration. The company has received significant grant funding from the Greek government and was designated a “Priority Investment of Strategic National Importance.” Clinical progress includes at least one ongoing trial since September 2019. The company operates primarily out of Greece with a focus on personalized medicine using ATMPs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Theracell Advanced Biotechnology.